Xenobiotic-urea conjugates; Chemical or biological?

Xenobiotica

Volumn 44, Issue 12, 2014, Pages 1055-1066

  Mitchell, Stephen C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Conjugation; Phase II; Urea; Ureido radical

Indexed keywords

AMINO ACID; AMINOPHENAZONE; ANDROGRAPHOLIDE; CARBON MONOXIDE; CAROXAZONE; CHLORINE; FORMALDEHYDE; ISOPROTURON; LAROPIPRANT; OXAZEPAM; ROSARAMICIN; TORCETRAPIB; UNCLASSIFIED DRUG; UREA; XENOBIOTIC AGENT;

BILE SECRETION; BIOTRANSFORMATION; CHEMICAL COMPOSITION; CHEMICAL REACTION; DEALKYLATION; DRUG CONJUGATION; DRUG TRANSFORMATION; HUMAN; NONHUMAN; POLYMERIZATION; REVIEW; SYNTHESIS; UREA CYCLE; XENOBIOTIC METABOLISM; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; UREA; XENOBIOTICS;

EID: 84910012156     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2014.948948     Document Type: Review

References (163)

1. Abel JL, Rowntree LG, Turner BB. (1914). On the removal of diffusible substances from the circulating blood of living animals by dialysis. II. Some constituents of the blood. J Pharmacol Exp Ther 5:611-23.
2. Alván G, Jönsson M, Sundwall A, Vessman J. (1977). First-pass conjugation and enterohepatic recycling of oxazepam in dogs; intravenous tolerance of oxazepam in propylene glycol. Acta Pharmacol Toxicol 40:16- 27.
3. Asami S, Saito K, Maeda A, Tateishi N. (2010). Anti-fatigue agents and oral compositions containing andrographolide as active ingredient. US Patent Appl. 20100144866 A1. (Assignee: Suntory Holdings Ltd, Osaka-sh, J apan), 10 June 2010, 4 p.
4. Backer HJ. (1943). Boerhaave's Ontdekking van het Ureum (Boerhaave's discovery of urea). Ned T Geneesk 87:1274-8.
5. Baumann E, Hoppe-Seyler F. (1874). Ueber Methyl-hydantoinsäure. Ber Deut Chem Ges 7:34-8.
6. Baumann E, von Mering J. (1875). Ueber das Verhalten des Sarkosins im Organismus. Ber Deut Chem Ges 8:584-9.
7. Bell SC, Ch ildress SJ. (1962). A rearrangement of 5-aryl-1,3-dihydro-2H-1,4-benzodiazepine-2-one 4-oxides. J Org Chem 27:1691-5.
8. Bernardi L, Coda S. (1975). 4H-3-Carbamoylmethyl-1,3-benzoxazin-2-one. South African Patent ZA7402435. (Assignee: Societa Farmaceutici Italia S.p.A., Italy), 30 April 1975. 7 p. Also, Jpn Kokai JP 50135088, 25 October 1975, 2 p.
9. Bernardi L, Coda S, Pegrassi L, Suchowsky GK. (1968). Pharmacological properties of some derivatives of 1,3-benzoxazine. Experientia 24:774-5.
10. Bernardi L, Coda S, Pegrassi L, Suckowsky GK. (1969). Carboxamidoalkyl-1,3-benzoxazines. US Patent 3,427,313.
11. (Assignee: Societá Farmaceutici Italia, Milan, Italy), 11 February 1969, 3 p. Also, GB Patent 1115759, 29 May 1968, 6 p.
12. Bernardi L, Coda S, Nicolella V, et al. (1979). Radioisotopic and synthetic studies related to caroxazone metabolism in man. Arzniem-Forsch 29:1412-16.
13. Bertagni P, Bianchi R, Marcucci F, et al. (1978). The enterohepatic circulation of oxazepam-O-glucuronide in guinea-pigs. J Pharm Pharmacol 30:185-6.
14. Bhatnagar VM. (1963). Clathrate compounds of urea and thiourea. J Sci Ind Res, Sect B, Phys Sci 22:44-9.
15. Bhatnagar VM. (1967). Clathrates of urea and thiourea. Zhurn Strukt Khim 8:568-6.
16. Blaut M, Braune A, Wunderlich S, et al. (2006). Mutagenicity of arbutin in mammalian cells after activation by human intestinal bacteria. Food Chem Toxicol 44:1940-7.
17. Blendermann H. (1882). Beitrage zur Kenntniss der Bildung und Zersetzung des Tyrosins im Organismus. Zeit Physiol Chem 6:234-62.
18. Blessing RH. (1983). Interdependence of carbon-nitrogen and carbonoxygen bond lengths in urea structures and in ureido ring structures. J Am Chem Soc 109:2776-83.
19. Bodansky M. (1927). Introduc tion to physiological chemistry. London: Chapman and Hall Ltd, 277-82.
20. Boerhaave H. (1727). A new method of chemistry. Part III. The practice of chemistry. Process 87. Urine-will yield an essential salt. (translated by P. Shaw, E. Chambers). London: J. Osborn and T. Longman, 193.
21. Boerhaave H. (1732). Elementa chemiae. Leipzig (Lipsiae): apud Casper Fritsch, 2:276-77.
22. Boerhaave H. (1741). A new method of c hemistry. Part II. Process 98 (mislabelled as CXVIII-118) (translated from the Latin by P. Shaw). Vol. 2. London: Longman, 198-9.
23. Boyd WJ. (1933). The isolation of amino-acids in the form of the corresponding carbamido-acids and hydantoins. 1. The derivatives of the mono-amino-monocarboxylic acids. Biochem J 27:1838-48.
24. Brousseau ME, Schaefer EJ, Wolfe EJ, et al. (2004). Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol. New Engl J Med 350:1505-15.
25. Brown BR. (1994). The organic chemistry of aliphatic nitrogen compounds. Oxford: Clarendon Press, 406-15.
26. Caccia C, Carfagna N, Fariello R. (1992). Caroxazone as antiparkinson MAO reversible inhibitor. PCT Int Patent Appl WO 9202224.
27. (Assignee: Farmitalia Carlo Erba S.r.l., Italy), 20 February 1992, 13 p. Also, Patent Applications, EP0495959 A1, 29 July 1992; CA2067170 A1, 11 February 1992.
28. Chang SW, Reddy V, Pereira T, et al. (2007). The pharmacokinetics and disposition of MK-0524, a prostaglandin D2 receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica 37:514-33.
29. Cheng K, Wu T-J, Wu KK, et al. (2006). Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. PNAS 103:6682-7.
30. Clark RW, Sutfin TA, Ruggeri RB, et al. (2004). Raising high-density lipoprotein in humans through inhibition of cholesterol ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24:490-7.
31. Cruickshank W. (1798). Experiments on urine and sugar. Section I. Experiments on urine. In: Rollo J, ed. Cases of the diabetes mellitus, 2nd edn. London: Gillet T, (for Dilly C), 438-51.
32. Cui L, Chan W, Qiu F, et al. ( 2008). Identification of four urea adducts of andrographolide in humans. Drug Metab Lett 2:261-8.
33. Cui L, Qiu F, Wang N, Xao X. (2004). Four new andrographolide metabolites in human urine. Chem Pharm Bull 52:772-5.
34. Cui L, Qiu F, Xao X. (2005). Isolation and identification of seven glucuronide conjugates of andrographolide in human urine. Drug Metab Dispos 33:555-62.
35. Da kin HD. (1909). The mode of oxidation in the animal organism of phenyl derivatives of fatty acids. Part VI. The fate of phenylalanine, phenyl-b-alanine, phenylserine, phenylglyceric acids and phenylacetaldehyde. J Biol Chem 6:235 -43.
36. Dakin HD. (1910 a ). The mode of oxidation of phenyl derivatives of fatty acids. A correction. J Biol Chem 8:35-9.
37. Dakin H.D. (1910 b). The fate of inactive tyrosine in the animal body toge ther with some observations upon the detection of tyrosine and its derivatives in the urine. The synthesis and probably mode of formation of Blendermann's para-hydroxybenzylhydantoin. J Biol Chem 8:25-33.
38. Dakin H.D. (192 2). Oxidations and reductions in the animal body, 2nd edn. London: Green and Co, 64.
39. Dalvie DK. (2008). Metabolism, excretion and disposition of torcetrapib in healthy volunteers. 15th North American regional ISSX Meeting , San Diego, CA: 12-16 October 2008. Drug Metab Rev 40:1-308 (Abstract 262
40. Dalvie D, Ch en W, Zhang C, et al. (2008). Pharmacokinetics, metabolism and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in human. Drug Metab Dispos 36:2185-98.
41. Damon DB, Dugger RW, Scott RW. (2003). Methods for preparing CETP inhibitors. US Patent 6,600,045 (Assignee: Pfizer Inc. New York NY), 29 July 2003, 4 p.
42. Davies M, Hopkins L. (1957). The bonding in urea and in the urea ion. Trans Faraday Soc 53:1563-9.
43. Davis FA, Sheppard AC. (1989). Applications of oxaziridines in organic synthesis. Tetrahedron 45:5703-42.
44. Davy J. (1811). An account of a new gas, with a reply to Mr Murray's last observations on oxymuriatic gas. J Nat Phil (Nicholson's J) 30: 28-33.
45. Davy J. (1812). On a gaseous compound of carbonic oxide and chlorine. Phil Trans R Soc Lond 102:144- 51. Also, J Nat Phil (Nicholson's J) (1812) 32:241-7.
46. Dean BJ, Chang S, Elipe MVS, et al. (2007). Metabolism of MK-0524, a prostagla ndin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans. Drug Metab Dispos 35: 283-92.
47. Dorland L, van Rhee AM, van Pelt J, et al. (1988). Mannosy-b(1-4)-Nacetylg lucosaminyl-b(1-N)-urea, a compound isolated from the urine of patients with b-mannosidosis. Glycoconjugate J 5:215-19.
48. Edwards K, Jackson H, Jones AR. (1970). Studies with alkylating esters-III: the metabolism and fate of methylene dimethanesulphonate. Biochem Pharmacol 19:1791-5.
49. Emmons WD. (1956). The synthesis of oxaziranes. J Am Chem Soc 78: 6208-9.
50. Folin O. (1905). Appr oximately complete analyses of thirty ?normal' urines. Am J Physiol 13:45-65.
51. Fourcroy AF, Vauquelin LN. (1799). Extrait d'un premier mémoire des cit. Fourcroy et Vauquelin, pour server ä l'histoire naturelle chimique et médicale de l'urine humaine, contenant quelque faits nouveaux sur son analyse et sur son altération spontanée. Ann Chim 31:48-71.
52. Fourcroy AF, Vauquelin LN. (1800). Deuxieme mémoire: pour server a l'histoire naturelle, chimique et médicale de l'urine humaine, dans lequel on s'occupe spé cialement des proprieties de la matière particulière qui le charactérise. Ann Chim 32:80- 112, 113-62.
53. Frias MA, W inik B, Franzoni MB, et al. (2008). Lysophosphatidylcholine-arbutin complexes form bilayer-like structures. Biochim Biophys Acta 1778:1259-66.
54. Friedmann E. (1931). Verhalten von dl-a-Naphthylalanin im tierischen Organismus. Biochem Zeit 242:266-81.
55. Frost AA, Pearson RG. (1961). Kinetics and mechanisms, study of homogenous chemical reactions. 2nd edn. New York: Wiley, 307.
56. Gornall AG, Hunter A. (1940). The behaviour of some uramido-acids in the nitrous acid method for the determination of amino-nitrogen. Biochem J 34:192-7.
57. Gorter K. (1911). Sur le principe amer de l'Andrographis paniculata N. Rec Trav Chim 30:151-60.
58. Gorter K. (1914). Sur l'andrographolide. Rec Trav Chim 33:239-43.
59. Griffin RJ, Burka LT. (1993). Metabolism and elimination of oxazepam in B6C3F1 and Swiss-Webster mice. Drug Metab Dispos 21:918-26.
60. He X, Li J, Gao H, Qiu F, et al. (2003a ). Six new andrographolide metabolites in rats. Chem Pharm Bull 51:586-9.
61. He XJ, Li JK, Gao H, et al. (2003b ). Four new andrographolide metabolites in rats. Tetrahedron 59:6603-7.
62. He X, Li J, Gao H, et al. (2003 c). Iden tification of a rare sulfonic acid metabolite of andrographolide in rats. Drug Metab Dispos 31:983-5.
63. Hemminki K. (1984). Urinary excretion products of formaldehyde in the rat. Chem Biol Interact 48:243-8.
64. Hildebrandt H. (1903). Auf das Verhalten der halogen substituierten Toluolen und Aminobenzoesäuren im Organismus. Beitr Chem Physiol Pathol 3:365-72.
65. Hoppe-Seyler FA. (1933). Lysi ne excretion in the urine in cystinuria. Hoppe-Seyler's Z Physiol Chem 214:267-70.
66. Horner L, Jü rgens E. (1957). Notiz Ü ber Darstellung und Eigenschaften Einiger isonitrone (Oxazirane). Chem Ber 90:2184-9.
67. Jaffe M. (1902). Antipyrylharnstoff, ein Stoffwechselderivat des Pyramidons. Ber Deut Chem Ges 35:2891-95.
68. Jahodá r? L, Leifertova I, Lisa M. (1985). Elimination of arbutin from the organism. Folia Pharmaceutica (Prague) 8:7-17.
69. Jencks WP, Regenstein J. (2010). Ionization constants of acids and bases. In: Lundblad RL, MacDonald FM, eds. Handbook of biochemistry and molecular medicine. Cleveland: CRC Press, 595-635.
70. Karanam B, Madeira M, Bradley S, et al. (2007). Absorption, metabolism, and excretion of [14C]MK-0524, a prostaglan din D2 receptor antagonist, in humans. Drug Metab Dispos 35:1196-202.
71. Kiep L, Maderner S, Seifert K. (2002). Metabolism of metamizol in early stages of the incubated hen's egg. Pharmazie 57:829-33.
72. Knowles JA, Ruelius HW. (1972). Absorption and excretion of 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one (oxazepam) in humans. Determination of the drug by gas-liquid chromatography with electron capture detection. Arzneim Forsch 22:687-92.
73. Krebs HA, Henseleit K. (1932). Studies on urea formation in the animal organism. Hoppe-Seyler's Z Physiol Chem 210:33-66.
74. Lamoureux GL. (1989). Plant metabolism of herbicides. In: Kato R, Estabrook RW, Cayen MN, eds. Xenobiotic metabolism and disposition. Proceedings of the 2nd International ISSX meeting, Kobe 1988. London: Taylor and Francis, 266-74.
75. Lehr S, Glä ssgen WE, Sandermann H, et al. (1996). Metabolism of isoproturon in soils originating from different agricultural management systems and in cultures of isolated soil bacteria. Int J Environ Anal Chem 65:231-43.
76. Lewis DE. (2012). Early Russian organic chemists and their legacy. Berlin: Springer-Verlag, 21.
77. Lin CC, Kim HK, Marco A, et al. (1986). Pharmacokinetics and metabolism of [14C]-rosaramicin in dogs. Antimicrob Agents Chemother 29:753-6.
78. Lin C, Puar MS, Schuessler D, et al. (1984a ). Isolation and identification of a metabolite of rosaramicin in human urine. Drug Metab Dispos 12: 51-6.
79. Lin CC, Chung M, Gural R, et al. (1984b ). Pharmacokinetics and metabolism of rosaramicin in humans. Antimicrob Agents Chemother 26:522-6.
80. Lindeboom GA. (1959). Bibliographia boerhaaviana. Leiden: EJ Brill, 81.
81. Lindeboom GA. (1968). Herman Boerhaave, the man and his work. London: Methuen, 333-4.
82. Lippich F. (1906). Ueber Isobutyl-hydantoinsäure und über eine Reaction zum Nachweis kleiner mengen von Leucin. Ber Deut Chem Ges 39:2953-6.
83. Lippich F. (1908). Uber Uramidosauren. Ber Deut Chem Ges 41: 2953-83.
84. Mashford PM, Jones AR. (1982). Formaldehyde metabolism by the rat: a re-appraisal. Xenobiotica 12:119-24.
85. Mateer JG, Marshall Jr EK (1916). The urease content of certain beans, with special reference to the jack bean. J Biol Chem 25:297-305.
86. Menozzi M, Arcamone F. (1977). Interazione d el brofoxine psicofarmaci e caroxazone con le protein plasmatiche. Conv Ital Sci Macromol [Atti] 3rd. Genoa, Italy, Copy-Lito: Instituto Ricerca Nerviano Farmitalia, Milan Italy, 121-3.
87. Mitsuba K, Ichihara K. (1927). Ü ber das Schicksal der Anthranilsäure im Tierkörper. Z Physiol Chem 164:244-54.
88. Moretti A, Caccia C, Carpentieri M, Carfagna N. (1984). Experimental studies with caroxazone. Lack of effects on drug met abolising enzymes. Monoamine Oxidase Diseases (Proc. Conf.). London: Academic Press, 537-46.
89. Morton ID, Hoggarth E. (1952). Carbonic acid and its derivatives. In: Rodd EH, ed. Chemistry of carbon compounds. Vol. 1B. London: Elsevier Publishing Co, 905-14.
90. Muecke W. (1983). Separation and purification of pesticide metabolites. In: Hutson DH, Roberts TR, eds. Vol 3. Progress in pesticide biochemistry and toxicology. Chichester: Wiley, 279-366.
91. Natanson M. (1856 a). Sur deux nouveaux modes de formation de l'uré e. Ann Chim Phys 48:109-11.
92. Neely WB. (1964). The metabolic fate of formaldehyde-14-C intraperitoneally administered to the rat. Biochem Pharmacol 13: 1137-42.
93. Neild GH. (1996). William Cruickshank (FRS-1802): clinical chemist. Nephrol Dial Transplant 11:1885-9.
94. Nicoll-Griffith DA, Seto C, Aubin Y, et al. (2007). In vitro biot ransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites. Bioorg Med Chem 17:301-4.
95. Orozco JLH, Aquilera RAB. (2011). Composition of labdane diterpenes extracted from andrographis pani culata, useful for the treatment of autoimmune diseases, and Alzheimer disease by activation of PPRgamma receptors. US Patent 8,084,495. (Assignee: Herbal Powers Corporation, Bradenton, FL) 27 December 2011. Also, PCT Appl. WO 2005074953, 18 August 2005.
96. Pagel W. (1982). Jean Baptiste van Helmont: reformer of science and medicine. Cambridge: Cambridge University Press.
97. Panossian A, Hovhannisyan A, Mamikonyan G, et al. (2000). Pharmacokinetic and oral bioavailability of andrograph olide from Andrographis paniculata fixed combination Kan Jang in rats and human. Phytomed 7:351-64.
98. Pelzer H, Maass D. (1969). Pharmacokinetik und metabolismus von 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benz odiazepin-2-on und dessen hemisuccinat beim menschen. Arzneim Forsch 19:1652-6.
99. Perrin-Ganier C, Schiavan F, Morel JL, Schiavan M. (2001). Effect of sludge-amendment or nutrient addition on the biodegra dation of the herbicide isoproturon in soil. Chemosphere 44:887-92.
100. Pluta T, Sadlej AJ. (2001). Electric properties of urea and thiourea. J Chem Phys 114:136-46.
101. Prakash C, Chen W, Rossulek M, et al. (2008). Metabolism, pharmacokinetics, and excretion of a cholesterol ester transfer protein inhibitor, torcetrapib, in rats, monkeys and mice: characterization of unusual and novel metabolites by high-resolution liquid-chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos 36:2064-79.
102. Prout W. (1817). Observations on the nature of some of the proximate principles of the urine, with a f ew remarks upon the means of preventing those diseases, connected with a morbid state of that fluid. Med Chir Trans 8:526-49.
103. Qui F, Cui L, Chen L, et al. (2012). Two novel creatinine adducts of andrographolide in human urine. Xenobiotica 42:911-16.
104. Quintus J, Kovar KA, Link, P, Hamacher H. (2005). Urinary excretion of arbutin metabolites after oral administration of bearberry leaf extracts. Planta Med 71:147-52.
105. Ratner S, Clarke, HT. (1937). The action of formaldehyde upon cysteine. J Amer Chem Soc 59:200-6.
106. Redemann CE, Riesenfeld FC, La Viola FS. (1958). Formation of biuret from urea. Ind Eng Chem 50:633-6.
107. Regnault V. (1838). Action du gaz ammoniac sec sur le gaz chlorocarbonique. Ann Chim Phys 69:180-3.
108. Rhode A. (1917). A met hod for the identification of phenylalanineuramino acid in the presence of urea and amino acid. Proc Am Soc Biol Chem, J Biol Chem 29:xxvii-iii.
109. Rhode A. (1918). A method for the identification of certain uraminoacids in the presence of amino acids and of urea. J Biol Chem 36: 467-74.
110. Roberts TR, Hutson DH. (1998). Metabolic pathways of agrochemicals: herbicides and plant growth regulators. Part 1. London: Royal Society of Chemistry, 705-2.
111. Rouelle HM. (1773). Observations sur l'urine humaine, et sur celle de vache et de cheval, comparées ensemble. J Méd Chir Pharm 40: 451-68.
112. Ruelius HW, Tio CO, Knowles JA, et al. (1979). Diastereoisomeric glucuronides of oxazepam. Isolation and stereoselective enzyme hydrolysis. Drug Metab Dispos 7:40-3.
113. Sakai A, Yasuda N, Fujiwara T, et al. (1987). Studies of 16-membered macrolide-urea adducts. Drug Metab Pharmacokinet 6:625-36.
114. Salkowski E. (1872). Ueber die Bildung der Schwefelsäure und des Harnstoffs und das Verhalten des Taurins im Thierkörper. Ber Deut Chem Ges 5:637-9.
115. Salkowski E. (1873 a). Ueber die Taurocarbaminsä ure. Ber Deut Chem Ges 6:744-6.
116. Salkowski E. (1873 b ). Ueber die Entstehung der Schwefelsaure und das Verhalten des Taurins im thierischen Organismus. Virchow's Arch Pathol Anat Physiol 58:460-508.
117. Salkowski E. (1877). Ueber den Vorgang der Harnstoffbildung im Thierkörper und den Einfluss der Ammoniaksalze auf denselben. Hoppe-Seyler's Z Physiol Chem 1:1-24.
118. Salkowski E. (1880). Weitere Beiträge zur Theorie der Harnstoffbildung: das Verhalten des Glycocoll etc. im Organismus (Zweiter Theil). Zeit Physiol Chem 4:100-32.
119. Salkowski E . (1882). Weitere Beiträge zur Kenntniss der Harnstoffbildung: das Verhalten der Amidobenzoësäure im Thierkörper. Zeit Physiol Chem 7:93-113.
120. Scheringer C. (1980). Bond-length corrections for external and internal vibrations in urea. Acta Cryst A36:814-18.
121. Schiffer J. (1881). Ueber das Schiksal des Sarkosins im menschlichen organismus. Zeit Physiol Chem 5:257-66.
122. Schiller J. (1967 ). Wöhler, l'urée et la vitalisme. Sudhoffs Archiv 51: 229-43.
123. Schindler G, Patzak U, Brinkhaus B, et al. (2002). Urinary excretion and metabolism of arbutin after oral administration of Arctosta phylos uvae ursi extract as film-coated tablets and aqueous solution in healthy humans. J Clin Pharmacol 42:920-7.
124. Schmidt CLA, Allen EG. (1920). Further studies on the elimination of taurine administerd to man. J Biol Chem 42:55-8.
125. Schmiedeberg O. (1878). Ueber das Verhaltniss des Ammoniaks und der primären Monaminbasen zur Harmstoff-bildung imThierkörper. Arch Exp Pathol Pharmakol 8:1-14.
126. Schmitz E, Fechner-Simon H, Schramm S. (1969). Triazane. 1. Bildung und Zerfall der N-N-N-Gruppierung. Liebigs Ann Chem 725:1-10.
127. Schmitz E, Ohme R, Schramm S. (1964). Isomere Oxime mit Dreiringstruktur. Chem Ber 97:2521-6.
128. Schultzen O. (1872). Die Entstehung des Harnstoffs im Thierkörper. Ber Deut Chem Ges 5:578-81.
129. Sherwin CP. (1922). The fate of forei gn organic compounds in the animal body. Physiol Rev 2:238-76.
130. Shorter J. (1978). The conversion of ammonium cyanate into urea-A saga in reaction mechanisms. Chem Soc Rev 7:1-14.
131. Si senwine SF, Tio CO. (1986). The metabolic disposition of oxazepam in rats. Drug Metab Dispos 14:41-5.
132. Sisenwine SF, Tio CO, Liu AL, Politowska JF. (1987). The metabolic fate of oxazepam in mice. Drug Metab Dispos 15:579-80.
133. Sisenwine SF, Tio CO, Shrader SR, Ruelius HW. (1972). The biotransformation of oxazepam (7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one) in man, mi niature swine and rat. Arzneim Forsch 22:682-7.
134. Sisenwine SF, Tio CO, Hadley FV, et al. (1982). Species-related differences in the stereoselective glucuronidation of oxazepam. Drug Metab Dispos 10:605-8.
135. Skurski P, Simons J. (2001). An excess electron bound to urea. 1. Canonical and zwitterionic tautomers. J Chem Phys 115:8373-80.
136. Sørensen SB, Bending GD, Jacobsen CS, et al. (2003). Microbial degradation of isoproturon and related phenylurea herbicides in and below agricultural fields. FEMS Microbiol Ecol 45:1-11.
137. Sturino CF, O'Neill G, Lachance N, et al. (2007). Discovery of a potent and selective prostaglandin D2 receptor antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta [b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 50:794-806.
138. Thierfelder H, Sherwin CP. (1914). Phenylacetyl-glutamin, ein Stoffwechsel-Produkt des menschlichen Körpers nach Eingabe von Phenyl-essigsäure. Ber deut Chem Ges 47:2630-4.
139. Thierfelder H, Sherwin CP. (1915). Phenylacetylglutamin und seine Bildung im menschlichen Körper nach Eingabe von Phenylessigsäure. Hoppe-Seyler's Zeit Physiol Chem 94:1-9.
140. Thongchai W, Liawruang rath B, Liawruangrath S. (2009). Arbutin determination in medicinal plants and creams. Int J Cosmet Sci 31: 87-96.
141. van Helmont JB. (1644). Opuscula medica inaudita, I. De Lithiasi, II. De Febribus, III. De Humoribus Galeni, IV. De Peste. Cologne (Coloniae Agrippinae): apud Jodocum Kalcoven. Caput II, No 30 -3.
142. Vaughan P, Donohue P. (1952). The structure of urea. Interatomic distances and resonance in urea and related compounds. Acta Cryst 5: 530-5.
143. Vauquelin M. (1818). Sur le cyanogène et sur l'acide Hydrocyanique. Ann Chim Phys 9:113-46.
144. Ville J. (1892). Transformation, dans l'economie, de l'acide sulfanilique en acide sulfanilocarbamique. C R Hebd Séanc Acad Sci (Paris) 114: 228-31.
145. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. (2006). On behalf of the Nautilus Study Group, 2006. Evaluation of safety and tolerability of prolonged-release nicotinic acid in a usual care setting. Curr Med Res Opin 22:417-25.
146. Volz M, Kellner HM. (1980). Kinetics and metabolism of pyrazolones (prop yphenazone, aminopyrine and dipyrone). Br J Clin Pharmacol 10:299S-308S.
147. Wada M. (1933). Eine neue Methode zur Darstellung von Aminen aus Aminosäuren. Biochem Zeit 260:47-51.
148. Wagman GH, Waitz JA, Marquez J, et al. (1972). A new Micromonospora-produced macrolide antibiotic, rosamicin. J Antibiotics 25:641-6.
149. Waitz JA, Drube CG, Moss Jr EL, Weinstein MJ. (1972). Biological studies with rosamicin, a new Micromonospora-produced macrolide antibiotic. J Antibiotics 25:647-52.
150. Walkenstein SS, Wiser R , Gudmundsen CH, et al. (1964). Absorption, metabolism, and excretion of oxazepam and its succinate half-ester. J Pharmaceut Sci 53:1181-6.
151. Weiland W. (1912). Beltrag zur Lehre von der Uraminosäurebildung. Biochem Z 38:385-93.
152. Werner EA. (1914). LXXXVIII. The constitution of carbamides. Part 1. The preparation of isocarbamides by the action of methyl sulphate on carbamides. J Chem Soc Trans 105:923-32.
153. Werner EA. (1923). The chemistry of urea. London: Longmans Green and Co, 1-209.
154. Wieruszeski J-M, Montreuil J, Strecker G, Farriaux J-P. (1985). Glycoconjugates. In: Davidson EA, Williams JC, Di Ferrante NM, eds. Proc. Eighth International Symposium, Houston, Texas, 8-13 September Vol. 2. New Yor k: Praeger, 125.
155. WHO. (1996). Isoproturon in drinking water. In: guidelines for drinking water quality; health criteria and other supporting information. 2nd edn. Vol. 2. Geneva; World Health Organisation. Also, background document for development of WHO ?Guidelines for drinking-water quality' WHO/SDE/WSH/03.04/37 (2003).
156. Williams RT. (1959). Detoxication mechanisms. The metabolism and detoxication of drugs: toxic substances and other organic compounds. 2nd edn. London: Chapman and Hall Ltd, 575.
157. Wöhler F. (1822 a ). Sur l'acide particulier qui se forme lorsque l'on combine le cyanogène avec les alcalis. Ann Chim Phys 20:353-9.
158. Wöhler F. (1822 b). Ueber die eigenthü mliche Säure, weiche Cyan (Blaustoff) von Alkalien aufgenommen wird. Ann Phys Chem 71: 95-103.
159. Wöhler F. (1825). Ueber Cyan-Verbindungen. Ann Phys Chem 79: 177-82.
160. Wöhler F. (1828 a). Ueber kü nstliche Bildung des Harnstoffs. Ann Phys Chem 88:253-6.
161. Wöhler F. (1828 b). Sur la formation artificielle de l'uree. Ann Chim Phys 37:330-4.
162. Wouters J, Evrard G, Durant F. (1994). The molecular structure of caroxazone, a reversible monoamine oxidase inhibitor. Acta Cryst C50:1774-7.
163. Zhou B, Zhang D, Wu X . (2013). Biological activities and corresponding SARs of andrographolide and its derivatives. Mini Rev Med Chem 13: 298-309.